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Mitogen-activated protein (MAP) kinases comprise an evolutionarily conserved family of proteins that
includes at least three vertebrate protein kinases (p42, p44, and p55 MAPK) and five yeast protein kinases
(SPK1, MPK1, HOG1, FUS3, and KSS1). Members of this family are activated by a variety of extracellular
agents that influence cellular proliferation and differentiation. In Saccharomyces cerevisiae, there are multiple
physiologically distinct MAP kinase activation pathways composed of structurally related kinases. The recently
cloned vertebrate MAP kinase activators are structurally related to MAP kinase activators in these yeast
pathways. These similarities suggest that homologous kinase cascades are utilized for signal transduction in
many, if not all, eukaryotes. We have identified additional members of the MAP kinase activator family in
Xenopus laevis by a polymerase chain reaction-based analysis of embryonic cDNAs. One of the clones identified
(XMEK2) encodes a unique predicted protein kinase that is similar to the previously reported activator
(MAPKK) in X. laevis. XMEK2, a highly expressed maternal mRNA, is developmentally regulated during
embryogenesis and expressed in brain and muscle. Expression ofXMEK2 in yeast cells suppressed the growth
defect associated with loss of the yeast MAP kinase activator homologs, MKK1 and MKK2. Partial sequence
of a second cDNA clone (XMEK3) identified yet another potential MAP kinase activator. The pattern of
expression ofXMEK3 is distinct from that of p42 MAPK and XMEK2. The high degree ofamino acid sequence
similarity of XMEK2, XMEK3, and MAPKK suggests that these three are related members of an amphibian
family of protein kinases involved in the activation of MAP kinase. Discovery of this family suggests that
multiple MAP kinase activation pathways similar to those in yeast cells exist in vertebrates.
Vertebrate mitogen-activated protein (MAP) kinases (or
extracellular-regulated kinases [ERKs]) are signaling mole-
cules common to pathways that regulate proliferation and
differentiation in many eukaryotes. Their activation occurs
in mitogenic responses, such as epidermal growth-factor
(EGF) stimulation of fibroblasts, insulin stimulation of skel-
etal muscle, and cytokine activation of hematopoietic cells.
In addition, MAP kinases are activated in differentiation or
nonmitogenic responses, such as oocyte maturation re-
sponse to progesterone, nerve growth factor (NGF) or
bradykinin induction in PC12 cells, catecholamine secretion
in response to nicotine in adrenal cells, and response to
seizure in the hippocampus (for reviews, see references 5,
38, and 52).
Numerous biochemical and developmental studies of the
activation of MAP kinase (p42 MAPK) have utilized matur-
ing Xenopus laevis oocytes. Progesterone-induced meiotic
maturation of oocytes induces an ,u phase-promoting factor
(MPF)-dependent kinase cascade that activates p42 MAPK
(12, 16, 40). In maturing oocytes the upstream activator of
MAP kinase (MAP kinase kinase [MAPKK]) is a 45-kDa
dual-specificity protein kinase able to phosphorylate p42
MAPK on threonine and tyrosine residues (32, 39). X. laevis
p42 MAPK RNA is expressed in the early oocyte as an
abundant maternal message and maintained at a constant
level during embryogenesis. At the mid-blastula transition
p42 MAPK RNA levels decline (56). Later in development,
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the p42 MAPK and MAPKK proteins can be detected in
many tissues of the larval and adult animal (26, 56).
While an understanding of the signaling events leading to
MAP kinase activation in vertebrates is just beginning to
emerge, more is known about signal pathways leading to
MAP kinase activation in Saccharomyces cerevisiae. In this
yeast, four MAP kinase family members (FUS3, KSS1,
MPK1, and HOG1) have been identified (2, 6, 9, 28). These
MAP kinase homologs function in three distinct signal trans-
duction pathways (Fig. 1). The most thoroughly defined of
these pathways controls the pheromone-induced mating
response (for reviews, see references 31 and 48). The protein
kinases STEll and STE7 and the functionally redundant
FUS3 and KSS1 kinases are components of this intracellular
signal pathway (for a review, see reference 11). Genetic
epistasis and biochemical analyses indicate that STEll
kinase acts before the STE7, FUS3, and KSS1 steps in signal
transmission (3, 13, 50, 57). Recently, it was demonstrated
that STE7 directly activates the MAP kinase homolog,
FUS3, by phosphorylation at the predicted Thr and Tyr
residues (10).
On the basis of structural homology to STE7, three other
S. cerevisiae kinases (MKK1, MKK2, and PBS2) are poten-
tial MAP kinase activators (1, 22). The PBS2 kinase is an
upstream activator of the HOG1-MAP kinase homolog, and
the functionally redundant MKK1 and MKK2 kinases act in
the PKC1-mediated signal transduction pathway upstream of
the MPK1-MAP kinase homolog (2, 22). Additionally, a
STEll-like enzyme (BCK1) has been found to act upstream
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FIG. 1. Comparison of signal transduction pathways of S. cerevisiae and vertebrates. Arrows indicate activation or stimulation. Question
marks indicate unknown factors active in the signaling pathway. Structurally related kinases are indicated at parallel positions in their
respective pathways.
of the MKK1 and MKK2 kinases (29, 42). This striking
reiteration suggests that the kinases comprising each path-
way function as a common unit, or module, and that this unit
has been conserved to mediate different physiological re-
sponses in yeast. We anticipate that a similar reiteration of
signal transduction modules will function in vertebrates to
mediate responses to different extracellular stimuli.
Members of the STE7 protein kinase family have been
isolated recently from Xenopus laevis (MAPKK), rats
(MAPKK), and mice (MAPK-ERK kinase [MEK]) (7, 26,
34). Each of these is a 45-kDa dual specificity protein kinase
that phosphorylates its substrate, MAP kinase, on the ty-
rosine and threonine residues necessary for activation (8, 32,
35). cDNA and predicted protein sequences suggest that the
three purified forms of the MAP kinase activators are
homologs (7, 27, 55). The predicted proteins encoded by the
two mammalian activators are identical at 383 of 384 resi-
dues, while the mammalian and X. laevis homologs share
92% identity.
The catalytic domains of all kinases are characterized by
15 highly conserved residues spread throughout 11 subdo-
mains (17). In both the MAP kinase and MAP kinase
activator subfamilies, homologies extend across larger
blocks of related amino acids within the catalytic domains.
We reasoned that additional members of the MAP kinase
activator family could be identified on the basis of these
extended regions of homology. We have used a polymerase
chain reaction (PCR) analysis with degenerate oligonucleo-
tides to identify novel members of the MAP kinase activator
family. Our analysis indicates that in X. laevis there are at
least three distinct members of the MAP kinase activator
family. We have examined the developmental tissue-specific
pattern of expression of these novel family members.
MATERIALS AND METHODS
Embryos and cell lines. X. laevis embryos were obtained
by standard procedures. The X. laevis XTC, XL, and X58
cell lines were obtained from Doug Melton (Harvard Uni-
versity) and the XIF (fibroblast) cell line was obtained from
David Shapiro (University of Illinois). The WMPA and
PRKT Rana pipiens cell lines were obtained from K. S.
Tweedle (Notre Dame).
Yeast strains, genetic procedures, and functional assays.
The S. cerevisiae strains used in this study have all been
previously described. The strain designations and the perti-
nent genotypes are as follows: 3233-1B, mkklA::LEU2
mkk2A::HIS3; and DIA56, mpklA::TRPI/mpk1A::TRP1 (22,
28, 29). Unless otherwise specified, we used media and
genetic procedures as described in Sherman et al. (46). Yeast
strains were transformed by the procedure of Ito et al. (24).
Mating assays were performed as described by Sprague (47),
sensitivity to high osmolarity medium was assayed as de-
scribed by Brewster et al. (2), and osmotic suppression of
temperature-dependent cell lysis was assayed as described
in Irie et al. (22).
PCR. The XMEK2 gene was amplified from 1 ,ul of a stage
17 X. laevis embryo cDNA library (109 plaques per ml) with
the XMO1 sense and XMO2 antisense degenerate oligonu-
cleotide primers (Table 1). PCR primers were synthesized on
an Applied Biosystems Inc. automated oligonucleotide syn-
thesizer, and Taq DNA polymerase was purchased from
Perkin-Elmer Cetus. All PCRs described in this paper con-
tained 10 mM Tris-HCl (pH 8.3), 50 mM KCI, 1.5 mM
MgCl2, 0.01% (wt/vol) gelatin, 200 ,uM all four deoxynucle-
oside triphosphates, 100 pmol of each primer, 2.5 U of
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TABLE 1. Degenerate oligonucleotide primers
Name DNA sequence' Amino acid Kinasesequence domainb
XMO1 5'-CGGATCCAYMGNGAYATHAARWSNAARAA-3' RDIKSKL/N VIb
XMO2 5'-GQMATTCYYTCNGGNGCCATRTA-3' EPAMY VIII
XMO3 5'-CTCGGATCCATHATNCAYMGNGA-3' II/MHRD VIb
XMO4 5'-GGTD2AGfAYTCNGGNGCCATRTA-3' EPAMY VIII
XMO5 5'-GGTCTAGAYTCNGGNGNCATRTA-3' EPSMY VIII
a The underlined nucleotides indicate the restriction enzyme sites added for cloning purposes. Primers XM01 and XM03 contain BamHI sites, primer XM02
encodes an EcoRI site, and primers XM04 and XMO5 encode XbaI sites. Degenerate nucleotide positions are indicated by the following International Union of
Biochemistry symbols: M = A or C; N = A, C, G, or T; W = T or A; R = A or G; H = A, C, or T; Y = C or T; and S = C or G.
b Domain refers to the kinase catalytic subdomains defined by Hanks and Quinn (16).
Elmer thermocycler were 1 min at 94°C, 1 min at 37°C, and
3 min at 63°C for 30 cycles, with a final 7-min extension at
63°C. The resultant PCR products were digested with EcoRI
and BamHI enzymes, purified by standard methods, and
ligated into the Bluescript II SK- vector. DNA was pre-
pared from recombinant clones, and the inserts were se-
quenced by the dideoxy method (Sequenase version 2.0,
DNA Sequencing Kit; U.S. Biochemical Corp.). The clone
containing the XMEK2 PCR fragment was designated
pXSTE7.
PCR-based analysis of individual X. laevis stage 17 cDNA
clones utilized the XMO3 sense and XMO4-XMO5 antisense
degenerate oligonucleotide primers (Table 1). Equimolar
amounts of all three primers were included in the PCRs as
described above. The PCR product of the appropriate size
was gel purified, digested with BamHI and XbaI enzymes,
and cloned into pUC118. Clones were sequenced by the
dideoxy chain termination method with Klenow polymerase
(45). All enzymes were purchased from New England Bio-
labs, Bethesda Research Laboratories, United States Bio-
chemicals, Stratagene, or Promega.
Analysis of cDNA libraries. A stage 17 X. laevis cDNA
library (Doug Melton, Harvard University) was screened by
plaque hybridization (44). The XMEK2 insert was removed
from pXSTE7 by digestion with HindIII and XbaI, gel
purified, and labeled by nick translation with Escherichia
coli DNA PolI to generate a probe (44). Hybridizations were
carried out at 65°C in 6x SSC (20x SSC is 3 M NaCl plus 0.3
M sodium citrate)-0.05x BLOTTO (lx BLOTTO is 5%
nonfat dried milk plus 0.02% sodium azide) from 1 to 3x
cot1/2. Filters were washed at high stringency through a
decreasing series of SSC washes (2x, lx, 0.5x, and 0.2x)
and exposed to Kodak XAR film overnight at -70°C with an
intensifying screen. Plaques that yielded a positive signal in
the initial screen were plaque purified and screened by
plaque hybridization a second time as described above (44).
Recombinant lambda plaques that reproducibly hybrid-
ized to the XMEK2 fragment of pXSTE7 were plaque
purified (44). These cDNA clones were categorized into
subfamilies by a PCR-based analysis with the degenerate
oligonucleotide primers XMO3, XMO4, and XMO5 (Table
1). DNA was prepared from plate lysates of individual
plaques of the clones selected for subsequent analyses and
digested at the EcoRI sites marking the endpoints of cDNA
insertion. cDNA inserts were gel purified and cloned into the
EcoRI site of pUC118. Clones were categorized into sub-
families by restriction maps. The clone with the strongest
reproducible pattern of hybridization and the largest cDNA
insert was designated pNC353 and used for subsequent
analyses.
Two X. laevis oocyte cDNA libraries and an X. laevis
stage 45 cDNA library were screened with pNC353. The
oocyte and stage 45 X. laevis embryo cDNA libraries were
provided by D. DeSimione (University of Virginia). Posi-
tively hybridizing clones were categorized into subfamilies
on the basis of the sequences at the 5' and 3' ends of the
cDNA inserts, restriction maps, and a PCR-based analysis of
internal regions.
DNA cloning and sequence determinations of XMEK2.
Isolates of XMEK2 cloned into the EcoRI site of pUC118 in
both orientations (pNC353 and pNC354) were used to gen-
erate banks of subclones by progressive unidirectional dele-
tion with exonuclease III (19). Subclones in these banks
were sequenced by the dideoxy-chain termination method
with Klenow polymerase, and the DNA sequence data were
assembled by using DBSYSTEM programs on a VAX-11/780
computer (45, 49).
DNA and protein alignments were performed with the
Genetics Computer Group programs (14) on a VAX-11/780
computer.
Site-directed mutagenesis of XMEK2. A lysine-to-arginine
mutation was created in the presumptive ATP-binding site of
XMEK2 by using an overlapping PCR technique with the
PCR primers XMEKMUT (XMEKMUT, 5' AGATTATG
GCTGTAAGGAGGATTCGCTCCAC 3'), the complemen-
tary oligonucleotide XMEK2MUTR, and the T3 and T7
primers (20). The template in these PCR was the XMEK2
cDNA cloned into the EcoRI site of the pBluescript II KS-
plasmid (Stratagene). This mutagenesis generates an A-to-G
transposition at position 534 in the XMEK2 cDNA (Fig. 3).
The final PCR product was digested with the restriction
endonuclease EcoRI, gel purified, and cloned into the EcoRI
site of pBluescript II KS-. The mutation at amino acid 160
was confirmed by sequencing, and the resulting plasmid was
called pXMEK2-R160. The position of the mutated amino
acid is numbered from the first methionine in the XMEK2
open reading frame (see Fig. 3).
Yeast expression plasmids. XMEK2 and XMEK2-R160
were cloned into a yeast CEN3 TRP1 ARS1 vector (pNC161)
that contains the triosephosphate isomerase (TPI1) promoter
(41). This construct allows for constitutive expression of
either the XMEK2 wild-type or the lysine-to-arginine
XMEK2 mutant protein in yeast cells. A 1.7-kb fragment
that contains the entire predicted open reading frame of the
protein was removed from either pNC353 or pXMEK2-R160
by digestion with Narl enzyme (position 1715; see Fig. 3),
end-repairing, and then digestion with EcoRI enzyme. The
TPI1 promoter was isolated as a 900-bp BglII-EcoRI frag-
ment from pGA1484 (G. Ammerer, Vienna, Austria). In a
single ligation step, the two fragments were joined at their
EcoRI ends and inserted into the pNC161 vector that had
been linearized by digestion with BamHI enzyme and end-
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FIG. 2. The MEK family of X. laevis. Alignment of the deduced protein sequences in domains VI and VII of XMEK2, XMEK3, and
MAPKK of X. laevis (27). Roman numerals refer to the conserved kinase domains defined by Hanks and Quinn (17).
repaired PstI. The desired recombinant clones were identi-
fied by restriction analysis and given the designation pNC341
or pNC341-R160.
The TPI1-XMEK2 allele was also cloned into a CEN4
ARS1 URA3 vector. A 2.5-kb TPII-XMEK2 fragment was
removed from pNC341 by digestion with the restriction
endonucleases Kpnl and HindIII and ligated into the com-
plementary sites in the vector YCplac33 (15). The desired
recombinant clone was identified by restriction analysis and
given the designation pNC373. Standard recombinant DNA
procedures were used for all plasmid constructions and
preparations (44). The vectors pNC161 and YCplac33 were
used as negative controls in the yeast expression studies (15,
41).
Plasmids containing a 2.7-kb SalI-PstI fragment encoding
the MKK1 gene and promoter in either YCplacll2 (p112-32)
or YCplacl95 (p195-32) were provided by K. Matsumoto
(22). The YEp13-MPK1 plasmid containing the MPK1 gene
and its promoter was provided by D. E. Levin (28).
Embryo RNA preparation. X. laevis embryos were lysed
in proteinase K (200 ,ug/ml) in 50 mM Tris-HCl (pH 7.5), 50
mM NaCl, 5 mM EDTA, and 0.5% sodium dodecyl sulfate
and incubated for 30 min to 1 h at 37°C (53). The lysate was
extracted with phenol-chloroform twice and ethanol precip-
itated. The precipitate was resuspended in diethylpyrocar-
bonate (DEPC)-treated water, an equal volume of 8 M LiCl
was added, and the RNA was precipitated overnight at
-20°C. The RNA was collected by centrifugation, washed
with 70% ethanol, resuspended in DEPC-treated water, and
stored at -800C.
RNA preparation from tissue culture cells. Cells were
grown in L-15 medium Leibovitz (Sigma) in 10% fetal bovine
serum with penicillin (50 U/ml) and streptomycin sulfate (50
,ug/ml) at 25°C. Cells were washed twice in saline and lysed
directly on the plate with solution D, and RNA was ex-
tracted from whole cells by the single-step guanidinium
isothiocyanate extraction with the following modification:
after the initial lysis and extraction with phenol-chloroform,
a second phenol-chloroform extraction was performed be-
fore ethanol precipitation (4). Samples were stored at -80°C.
Northern blot analysis. Total cellular RNA (10 pg) was
loaded on a formaldehyde-1% agarose gel (44). Standard
methods were used for transfer to a Magnagraph membrane
and subsequent hybridization with a randomly labeled probe
(44). After hybridization, each blot was stripped of radioac-
tivity and reprobed with an ornithine decarboxylase PCR
fragment as an internal blotting control (23).
Whole embryo in situ analysis. Whole embryo in situ
analysis was performed on staged albino embryos as de-
scribed by Hemmati-Brivanlou et al. (18). XMEK2 an-
tisense- and control sense-strand probes were generated
from linearized pNC353 plasmids. Probes were synthesized
by incorporating digoxigenin-1l UTP by using bacterial
RNA polymerases (T3 or T7) (18). The hybridization signal
was detected by secondary antibody against digoxigenin cou-
pled to alkaline phosphatase, followed by development with
nitroblue tetrazolium - 5 - bromo -chloro - 3 - indolyl-phosphate
toluidinium (NBT-BCIP) (Promega). For staining analysis,
whole embryos were cleared with a 2:1 solution of benzyl
benzoate-benzyl alcohol (BB-BA) (18).
Nucleotide sequence accession number. The EMBL acces-
sion number for XMEK2 is Z22736.
RESULTS
Identification of members of the XMEK family. A cDNA
library from X. laevis embryos (Nieuwkoop stage 17) was
screened by PCR-based amplification (36, 43). DNA se-
quence analysis of cloned amplification products identified a
PCR product with an open reading frame of 50 amino acid
residues. The predicted protein encoded by this fragment
showed strong similarity to the members of the STE7 family
of protein kinases. Members of this family include STE7,
BYR1, MKK1, MKK2, PBS2, and WIS1 (1, 22, 33, 51, 54).
The predicted amino acid sequence of the PCR product
mapped to kinase catalytic subdomains VIB, VII, and VIII
(17). To identify X. laevis cDNA clones containing this
sequence, the PCR-amplified fragment was used as a probe
in a plaque hybridization screen of a stage 17 X. laevis
embryonic cDNA library. Ten positive plaques were identi-
fied in a screen of 4 x 106 PFU from this cDNA library.
A PCR-based amplification was utilized to determine
whether the sequences of the 10 positive clones were similar
or different (see Materials and Methods). This analysis
allowed us to group the clones into three categories. Three of
the cDNA clones contained regions that encoded 50 amino
acids identical to those in the original amplified fragment.
Restriction analyses of the three clones suggest that they
represent different lengths of cDNAs derived from the same
gene. We have named the gene coding for these cDNA
clones Xenopus MAPK-ERK kinase 2 (XMEK2) (Fig. 2).
Two of the 10 cDNA clones contained identical DNA
fragments encoding a predicted protein fragment that was
related to XMEK2. The single open reading frame in these
clones encodes a unique protein kinase with 63% identity to
XMEK2 (Fig. 2). The gene encoding these cDNAs was
named Xenopus MAP-ERK kinase 3 (XMEK3). The
XMEK2 and XMEK3 predicted proteins are distinct from
the biochemically identified X. laevis MAP kinase activator
protein (27). Within subdomains VI to VIII, XMEK2 is 62%
identical and XMEK3 is 46% identical to the X. laevis MAP
kinase activator protein (Fig. 2). On the basis of the struc-
tural similarity, XMEK2 and XMEK3 represent two new
members of the MAP kinase activator family in X. laevis.
The remaining five clones were weak positives that pro-
duced anomalous results under the same PCR conditions:
two of these cDNA clones did not produce a PCR product.
In the remaining three, a fragment was amplified from the
lambda exonuclease gene (data not shown).
Primary structure of XMEK2. We sequenced the XMEK2
clone with the largest cDNA insert (1,807 nucleotides) on
both strands (Fig. 3). The DNA sequence of the clone
encodes a single open reading frame starting at position 2
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AGCAQCATGGGGGTTGCTGCATTGCAGCCTTCA TTTGGTAGCGAATATATTAKCAATGGCGACTTCCA ACCCTAGCGGCAGATGAGATCGGCTCGGATTCCAAGCGTC
A Q W G L L H C S L H L V A N I L T M A T S N P S G S S G S S A G L G F Q G Q S
GCCTTCAGATAAACCGTGACAATACACA
L Q I N L C D N T Q
130 1 170 190 210 230
TCAGCAACACAGCACAGTCAACAGCATAGCA TGGeCACCCGGCCTTCAAATCGACAGCAAAATTCACACTGAACCCACTATTCAGAGTAC
Q Q H S T V N S M Q G K R K A L X L N F A N P A F X S T A K F T L N P T I Q S T
250 270 290 310 330 350
H V M B K L D A I R K L E T * Y QC TTCGCT S GG A G AG CLTGS GT N TAQ A >TQ NARGLT
370 390 410 430 450 470
ArAGAGaGTT6CGACAQCACGTATTG.AATCCTCTGGAAAAiTTAAAGCTGTCTCCAACATGGCTCCGAAGCTAGAGGGAATTGGCGGGGAGCTTA
E R L R T H S I E S S G X L X L S P E Q W D F T A E D L X D L G E I G R G A Y
490 510 530 550 570 590
TG=CCAGT*AATAAAATGAGTCATACTPCdQCGTGGGCAGAITTATGGCTGTTAAAGRGCATTCGCTCCACAGTGGATEGAGXAZAAGAQAGKAGCAGCCTCCMTCATGATCTGGCATGTGGTGATS V N K M S H T P S Q I M AVKX I RS T V D EKXE Q K Q L L MD L D V VMN
610 630 650 670 690 710
GCGG;AGTAGTGACTG;CCCGT'ACATAGTCC,kC'-TTTACGGAGCACTATTCAGAGAGGGTGACTGCTGGATCTGTATGGAGCTCATGGCTACCTCGTTCGACAAGTeTTACvAAATATGTATA
R S S D C P Y I V Q F Y G A L F R E G D C W I C M E L M A T S F D X F Y K Y V Y
730 750 770 790 810 830
TAGTTTTTTGATGACG;TTATTCCAGAGGAAATCCTAGGCATACTTTAGCGACTGGAAAGCCTTAAATTQCTTAAAAGAAAACTTGAAAATCATTCACAGAGACATCAAACCTTC
S F L D D V I P E E I L G K I T L A T V K A L N E L K E N L K I I H R D I K P S
850 870 890 910 930 950
CAATATTCTC6CTGGACACAAATGGAAACATTAAACTCTGTGACTTTGGCATTAGCGGGCAGCTGGTGGATTCCATTGCCAAGACCAGAGATGCCGGTTGCAGACCTTlACATGGACCCGA
N I L L D T N G N I K L C D F G I S G Q L V D S I A K T R D A G C R P Y M A P E
970 990 1010 1030 1050 1070
AAGGATAGACCCAAGTGCATCQCCAGaGCAGATATGATGTCCGGTCCGATGTGTGGAGCCTTGGGATCACGCTATATGAGTTGGCTACGGGCCGGTTTCCATACCCCAAGTGGAACAGTGT
R I D P S A S P Q G Y D V R S D V W S L G I T L Y E L A T G R F P Y PK W N S V
1090 1110 1130 1150 1170 1190
ATTTG;ATCAGCTGACACAGGTTGTGAAAGGGGACCCCCCTCAGCTGAGCAACTCGGAAGAGAGAGAGTTCTCCCCGAGCTTTACCAGTTTTGTGAATQGCTGCCTTACCQAGGACGAGTC
F D Q L T Q V V X G D P P Q L S N S E E R E F S P S F T S F V N Q C L T K D E S
1210 1230 1250 1270 1290 1310
AAAAAGACCAAAATACAAAGAACTTTTGAAACATCCCTTCATCTLTGATGTATGAAGAGCGCACAGTGGACGTGAGAGGYTATGTTGGCAAAATCCTGGAGCAGATGCCAGTTTCCCCCCAG
K R P K Y K E L L K H P F I LM Y E E R T V D V A G Y V G K I L E Q M P V S P S
1330 1350 1370 1390 1410 1430
CTCCCCGATGTATGTCGATTkGACCCAGCCATTACGCAAACTTCTAGCGACAAGGGCTGTGAGTGAACCAAGACGCAAAGAGATTCCAACCCGCGACTGTCGGTGATCGCCCQTTCTCCCT
S P M Y V D *
1450 1470 1490 1510 1530 1550
CGCTCQCAGCCCACGTGCAATAAG;ATCGGTGTTCGTTTAATTTCCCTTCCATCGTGTCTG;TGTr.CTACCGTCACATGTAAATTG;CATeCCCCCCCCTCCTrTTTAAnGAAACGGCTGGTCT
1570 1590 1610 1630 1650 1670
CATGGGAC16CCTGTTTG95GT7G1ACAGCCACGTGTCCACAACCTATTCTTAACTGGGTT70AAAACAACTAGATGCGC TGGATCATAA
1690 1710 1730 1750 1770 1790
ACAGATTTTe.TCTTTATGA'GAAAGGAAAGTTCTGGCGCCATCGTACAACCCGTTACCCTGTCCCAGAGGTGGGCAAAGAATATGAATTATATAAATATATATATAT-T--TTA-TTATTTTTA
FIG. 3. Nucleotide and predicted protein sequences of XMEK2. The nucleotide sequence of the coding strand is shown. The sequenced
insertion found for XMEK2 variant clones is indicated at position 153 (see Results [primary structure of XHEKZ]). The first methionine in
the predicted protein sequence is underlined.*, every 10th position in the nucleotide sequence; *, termination codon.
and terminating with a TGA translation termination codon at
position 1337.
Sequence analyses of independently isolated XMEK2
cDNAs from oocyte and stage 45 cDNA libraries suggest
that alternately processed forms of XMEK2 are expressed.
In these cDNA libraries, the primary structure of the major-
ity of XMEK2 transcripts is identical to that of the original
stage 17 cDNA (data not shown). Surprisingly, a variant was
identified in the oocyte mRNA population that contains a
33-bp insertion after nucleotide 153. This insertion adds 11
amino acids to the XMEK2 protein predicted by the original
cDNA clone (Fig. 3).
The deduced protein sequence of the XMEK2 cDNA
clone contains all the conserved signature motifs character-
istic of protein kinases (17) (Fig. 3). Searches of current
protein data bases by using the FASTA algorithm (SwissProt
release no. 21) revealed that the sequence of this predicted
X. laevis protein kinase is distinct from any listed sequences
(37). However, consistent with the homologies noted in the
small PCR fragment, the entire sequence shows a high
degree of relatedness to six yeast protein kinases (STE7,
PBS2, BYR1, MKK1, MKK2, and WIS1), the MAP kinase
activator from X. laevis (MAPKK), and two mammalian
protein kinases (MEK and MAPKK) (Fig. 4) (1, 7, 22, 27, 33,
51, 54, 55). Values for identity (similarity) of aligned se-
quences by a BestFit analysis ranged from 34 to 47% identity
and 44 to 67% similarity. Conservation of the amino acid
sequence was most striking within the catalytic domains of
these proteins (Fig. 4). Values for the percent identity in an
alignment of the XMEK2 catalytic domain with the other
MAP kinase activator family members ranged from 39 to
51%, while the identities within the regulatory domains were
17 to 25% (Fig. 5). The only striking similarity within the
regulatory domains of the MAP kinase activators is the high
serine content near the N terminus. In XMEK2, 7 of 20
amino acid residues downstream from the first methionine in
the open reading frame are serine residues (Fig. 2).
XMEK2 provides MAP kinase activator function in S.
cerevisiae. To test whether the structural similarity of
XMEK2 to members of the MAP kinase activator family has
functional significance, we asked whether expression of
XMEK2 would suppress the various response defects asso-
ciated with loss of different MAP kinase activators in S.
cerevisiae (Fig. 5). We first tested XMEK2 for the ability to
provide MKK1 and MKK2 function in the PKC1-mediated
signal pathway (Fig. 1). In this pathway, signal transmission
is dependent on an ordered kinase cascade in which the
BCK1 gene product functions before MKK1 and MKK2 and
the MPK1 gene product functions after MKK1 and MKK2
(22, 28, 29).
A strain with deletions of theMKKI andMKK2 genes was
transformed with either a plasmid that allows for constitutive
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FIG. 4. Alignment of the deduced protein sequences of protein kinases in the STE7 kinase family. Uppercase letters designate amino acid
residues in the aligned sequences that were either identical or conservative substitutions. Lowercase symbols indicate amino acid residues
that were not conserved. The consensus sequence contains residues that were identical in six of the seven aligned sequences. Residues
conserved in all kinases are indicated by boldface type in the consensus sequence (17). Roman numerals above the sequences refer to
subdomains of the protein kinase catalytic domains described by Hanks and Quinn (17). The sequences are those for XMEK2 (Fig. 3),
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FIG. 5. Percent identities for the catalytic domains of the STE7
protein kinase family. Sequence comparisons were limited to the
region bounded by the conserved GXGXXG motif of subdomain I
and the conserved R of subdomain XI (17). The percentage of
identical amino acids was calculated for each pair by using the
Genetics Computer Group BestFit program to maximize the number
of matches. The sequences are the same as those listed in Fig. 4.
expression of wild-type XMEK2 (pNC341) or a substitution
derivative, XMEK2-R160 (pNC341-R160). XMEK2-R160
contains a lysine-to-arginine substitution at the presumptive
catalytic lysine in subdomain II of XMEK2 (Fig. 3). To
provide negative and positive controls for the functional
assay, the same strain was transformed with vector
(pNC161) or a plasmid that overexpresses MKK1 (p112-
MKK1).
Loss of MKK1 and MKK2 results in a temperature-
dependent deficiency in cell wall construction that causes
cell lysis at the restrictive temperature (37°C) in the absence
of osmotic stabilizers (Fig. 6A, vector) (22). Expression of
XMEK2 suppressed the defect associated with loss of
MKK1 and MKK2 and allowed cells to form colonies at the
restrictive temperature (37°C) without osmotic stabilizers
(Fig. 6A, XMEK2). The extent of suppression by XMEK2 is
at least equivalent to the level of complementation by MKK1
(Fig. 6A, MKK1) (22). Suppression of the temperature-
dependent cell lysis defect is dependent on XMEK2 kinase
function, since mkklA mkk2A cells transformed with
XMEK2-R160 did not grow at the restrictive temperature in
the absence of osmotic stabilizers (Fig. 6A, XMEK2-R160).
The above result does not distinguish whether suppression
of MKK1 and MKK2 by XMEK2 is mediated by the
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FIG. 6. Expression of XMEK2 suppresses the temperature-sen-
sitive growth defect of a mkklA mkk2A strain. (A) Strain 3233-1B
(mkklA/mkk2A) was transformed with plasmids containing the indi-
cated genes (XMEK2, pNC341; MKK1, p112-32; XMEK2-R160,
pNC341-R160; and vector, pNC161), and the transformants were
streaked onto YPD medium alone or supplemented with 1 M sorbitol
and incubated at 37°C for 2 days. (B) Strain DLA56 (mpklA) was
transformed with plasmids containing the indicated genes (XMEK2,
pNC374; MKKI, p195-32; MPK1, YEpl3-MPK1; and vector, YC-
plac33) and treated as described for panel A.
ately activating targets of the pathway. To address this issue
we asked whether expression of XMEK2 was able to sup-
press the defect associated with loss of MPK1. A strain with
a deletion of the MPKJ gene was transformed with plasmids
that express XMEK2 (pNC341) or MKK1 (p195-32). As
controls the same strain was transformed with vector
(YCplac33) or MPK1 (YEp13-MPK1). Transformants were
tested for the ability to grow at the restrictive temperature
(37°C) in the absence of osmotic stabilizers. As expected, the
defect associated with the loss of MPK1 was complemented
by its expression (Fig. 6B, MPK1) (28). Expression of
XMEK2 or MKK1 did not suppress the defect (Fig. 6B,
XMEK2 and MKK1) (28). These results are consistent with
XMEK2 function in the PKC1-mediated pathway requiring
MAP kinase activity. They strengthen the argument that
XMEK2 is a MAP kinase activator.
In contrast to the results with the PKC 1-mediated path-
way, XMEK2 expression did not suppress the response
defects caused by loss of the STE7 and PBS2 MAP kinase
activators. These two enzymes function in the mating and
osmoregulation signal pathways, respectively. Strains with a
deletion of STE7 (E929-6C-18) expressing either XMEK2
(pNC341) or vector (pNC161) did not mate with an appro-
priate tester strain and did not activate transcription of a
pheromone-inducible reporter gene (Fusl-LacZ) (data not
shown). Strains with a disruption ofPBS2 (GBH38) express-
ing either XMEK2 (pNC341) or vector (pNC161) did not
grow on medium supplemented with 0.9 M NaCl (data not
shown). Therefore, XMEK2 provides MAP kinase activator
function in only one of the yeast signal pathways. This
discrimination could reflect an isotype specificity for the
PKC1 pathway. Alternatively, XMEK2 may function in the
three yeast pathways, but each pathway may have a different
signal threshold for response.
Temporal patterns of XMEK2 and XMEK3 expression. To
examine the developmental expression of XMEK2, we per-
XMEK2
ODC__
FIG. 7. Northern blot analysis of XMEK2 and XMEK3 expres-
sion. Equal amounts of total RNA (10 pLg) from whole fertilized X.
laevis embryos at the indicated stages of development (A) or from
the indicated frog cell lines (B) were analyzed by Northern blots.
Blots were hybridized to either a radiolabeled XMEK2, XMEK3, or
ornithine decarboxylase (ODC) probe as indicated. (A) The same
blot was hybridized to each of the three probes. Following hybrid-
ization to XMEK2, the blot was stripped and rehybridized to the
XMEK3 and ornithine decarboxylase probes. (B) The same blot was
hybridized to the XMEK2 and ornithine decarboxylase probes.
formed a Northern blot analysis of RNA derived from
different stages of X. laevis embryonic development. A
single 2.7-kb transcript was identified (Fig. 7A). XMEK2 is
expressed as a maternal RNA, which decays during the
mid-blastula transition, as evidenced by decreasing levels of
the XMEK2 transcript at stage 9. XMEK2 mRNA is ex-
pressed as a zygotic transcript by early neurula, stage 17
(Fig. 7A). The level of XMEK2 mRNA expression was
examined in a number ofX. laevis cell lines (XTC, XIF, XL,
and X58) and R. pipiens cell lines (Fig. 7B). XMEK2
expression was detected in all cell lines and was highest in
the XIF fibroblast cell line.
The XMEK2 transcript is at least 900 bp larger than the
cDNA insert isolated from the X. laevis stage 17 library. On
the basis of the sequences of a number of independently
isolated XMEK2 cDNAs, we believe that most of this size
discrepancy can be accounted for by mispriming at an
adenine-rich internal region in the XMEK2 message (Fig. 3).
We identified multiple XMEK2 cDNA clones with 2.2-kb
inserts that were identical to the sequenced cDNA at the 5'
end but contained characteristic poly(A) tails at their 3' ends
(data not shown). Thus, the 3' end of the sequenced XMEK2
cDNA clone is probably not the true terminus but a trunca-
tion. The fact that the reading frame at the 5' end of the
XMEK2 cDNA is open to the end of the insert raises the
possibility that sequences are missing from the 5' end of the
XMEK2 cDNA clone. Although the predicted protein se-
quence may be incomplete, this possibility does not limit the
analyses or conclusions made in this study.
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FIG. 8. XMEK2 expression during embryogenesis. Embryos were analyzed by whole mount in situ hybridization to XMEK2 RNA.
Shown are X. laevis embryos hybridized with either XMEK2 antisense (A and C) or sense (B) strand RNA probes. (A and B) The stages of
embryonic development from top to bottom are 17, 24, 32, and 37 (36). In panel B, the intensity of the background is different from that of
panel A because of the difficulty of photographing embryos which do not hybridize to the probe. (C) Enlargement of a stage 37 embryo
hybridized with the anti-sense strand RNA probe for XMEK2.
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is distinct from that of XMEK2 (Fig. 7A). While this
transcript is detected at all stages examined, the levels of the
XMEK3 transcript show less fluctuation during development
than do those of the XMEK2 transcript (Fig. 7A).
Spatial pattern of XMEK2 expression. To determine the
pattern of XMEK2 expression during organogenesis, we
performed whole-embryo in situ analysis of staged X. laevis
embryos (Fig. 8A). At stage 17, XMEK2 is initially ex-
pressed in the dorsal region of the embryo in a diffuse
pattern. Subsequently, expression of XMEK2 occurs in the
early stages of development of the central nervous system,
including the brain, spinal cord, and eye. Later (stage 24)
expression is found in the hindbrain, midbrain and forebrain,
and the somites. By stage 32, expression is detected in the
cranial neurons. Expression in the brain is increased, while
expression in the spinal cord has decreased by stage 37 (Fig.
8C). No staining is evident in control embryos by using sense
RNA (Fig. 8B). This pattern of XMEK2 RNA expression is
similar to that of MAP kinase, for which expression is
highest in the central nervous system, including the brain,
spinal cord, cranial and spinal nerves, and retina (56).
DISCUSSION
We have identified two cDNA clones (XMEK2 and
XMEK3) that code for novel members of the protein kinase
family in X. laevis. The C-terminal portion of the predicted
XMEK2 protein encodes the hallmark amino acid residues
and conserved catalytic subdomains I to XI, which are
characteristic of a protein kinase (17). The single exception
is a conservative Asp-to-Glu change at residue 195 in sub-
domain III (Fig. 3). In surveys of the protein kinase family,
substitutions have been found at all invariant residues, with
the exception of the catalytic lysine in subdomain II (17).
The amino acid sequences in domains VI (DIKPSN) and
VIII (GCRPYMAPER) suggest that this predicted protein
kinase is a member of the serine/threonine kinase subfamily
(30). Since the characterized MAP kinases require both
tyrosine and threonine phosphorylations for activation, ki-
nases that singly activate MAP kinase must be capable of
phosphorylating both types of residues. No definitive motifs
that distinguish single specificity protein kinases from dual
specificity kinases able to phosphorylate both tyrosine and
serine/threonine residues have been identified. However, the
presence of a small noncharged amino acid between Pro and
Asn in domain VIB (in this clone, the Ser in DIKPSN)
loosely correlates with dual specificity (30). The isolation of
XMEK2 cDNAs with insertions of 11 amino acids in the N
terminus demonstrates that XMEK2 is subject to alternative
processing.
To address the question of whether XMEK2 is also
functionally related to other MAP kinase activator proteins,
we tested its ability to function in the PKC1-mediated MAP
kinase activation pathway of S. cerevisiae. In this pathway,
MKK1 and MKK2 are redundant MAP-kinase activator
proteins that function after the BCK1 kinase and before the
MAP kinase homolog MPK1 (Fig. 1) (22, 28, 29). We
demonstrated that expression of XMEK2 in yeast cells
suppressed the cell lysis defect associated with loss of
MKK1 and MKK2. The ability to correct the PKC1 pathway
defect was specific for the MKK1 MKK2 step because
XMEK2 expression did not suppress loss of MPK1. These
results are consistent with XMEK2 providing MAP-kinase
activator function.
The limited sequence information for the second cDNA
clone (XMEK3) reveals an open reading frame that encodes
amino acid residues characteristic of kinase subdomains VI
to VIII. While the predicted XMEK2 and XMEK3 protein
kinases are unique, they do share significant identities with
the members of the STE7 kinase family (1, 7, 22, 27, 33, 51,
54, 55). The extent of these identities is within the range of
relationships among the previously identified members of
this family.
MAPKK, which was previously the sole identified mem-
ber of this family in amphibians, XMEK2, and XMEK3
share 46 to 63% identity at the amino acid level (Fig. 2) (27).
In X. laevis, allelic differences or divergence between dupli-
cate copies of a gene within the tetraploid genome is gener-
ally less than 10% at both the nucleotide and amino acid
levels (25). The DNA sequences in subdomains VI to VIII of
multiple, independently isolated XMEK2 cDNA clones rep-
resenting both XMEK2 alleles showed 100% identity at both
the nucleotide and amino acid levels to the original stage 17
XMEK2 cDNA clone (data not shown). The similarities
between XMEK2 and XMEK3 at the nucleotide and the
amino acid levels are no greater than the similarities between
either of these genes and MAPKK. On the basis of these
differences, we conclude that the predicted protein kinases
encoded by XMEK2 and XMEK3 represent two novel and
unique members of the MAP kinase activator family in X.
laevis.
In amphibians, biochemical studies have identified a single
MAP kinase (p42 MAPK) and a single MAP kinase activator
(MAPKK). p42 MAPK and MAPKK are expressed in sev-
eral tissues, including the central nervous system, kidneys,
liver, and intestine and the hematopoietic system (26, 56).
The patterns of XMEK2 expression in X. laevis during early
embryonic and larval development are similar to those of p42
MAPK and MAPKK (26, 56). In the embryo, XMEK2,
MAPKK and p42 MAPK are expressed as abundant mater-
nal messages. The patterns of expression of p42 MAPK and
MAPKK have not been examined during later embryonic
development, and comparisons to XMEK2 expression can-
not be made at this time. A murine homolog of XMEK2
(MMEK2) displays a pattern of expression similar to that of
XMEK2 (21). MMEK2 is abundantly expressed in adult
brain and muscle. Interestingly, XMEK2, MAPKK, and p42
MAPK are all expressed in the central nervous system.
These results and the demonstrated coexpression of
XMEK2 and p42 MAPK in XTC cells suggest that certain
cell populations are capable of expressing at least two MAP
kinase activators (56).
The pattern of expression of XMEK3 in embryonic devel-
opment is distinct from that of XMEK2, p42 MAPK, and
MAPKK. Whereas XMEK2 is expressed most abundantly in
oocytes and then at markedly lower levels later in develop-
ment, the levels ofXMEK3 vary less. These unique patterns
and the identification of multiple members of the MAP
kinase activator family suggest that parallel signaling path-
ways exist in X. laevis.
Precedence for parallel but structurally related signaling
pathways exists in S. cerevisiae in which conserved units of
protein kinases function in three independent pathways.
Equivalent tiers in these functionally distinct signaling path-
ways are composed of MAP kinase and MAP kinase activa-
tor family members (11) (Fig. 1). Since each yeast pathway
stimulates a different response and requires a unique extra-
cellular stimulus, different stages of embryonic development
in X. laevis could require activation of distinct MAP kinase-
dependent signal transduction pathways. Previous studies of
X. laevis MAP kinase-dependent signal transduction have
been confined to oocyte maturation. Analyses of MAP
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kinases in later stages of amphibian development should
shed light on whether MAP kinases distinct from p42 MAPK
might function with XMEK3. The homologies that we have
noted at the structural and functional levels between MAP
kinases and MAP kinase activators in S. cerevisiae and in
vertebrates along with the recent discoveries of multiple
family members within both S. cerevisiae and X. laevis
suggest that common reiterated units of protein kinases are
utilized for intracellular signal transmission in both systems.
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